⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CCCC News
C4 Therapeutics, Inc.
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
globenewswire.com
CCCC
Insmed Appoints Two New Directors to Its Board
prnewswire.com
CCCC
INSM
Eastern Europe Construction Market - Share, Size, Trends and Growth Forecasts, 2026-2031 | EU Funding and Renewable Energy Drive a USD 652.68 Billion Market by 2031
globenewswire.com
BAM
CCCC
Form 8-K
sec.gov
CCCC
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
globenewswire.com
CCCC
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
globenewswire.com
CCCC
Form 8-K
sec.gov
CCCC
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CCCC
Form 8-K
sec.gov
CCCC